4.7 Article

Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence

期刊

BIOENGINEERED
卷 12, 期 2, 页码 11108-11125

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/21655979.2021.2000122

关键词

Multi-omics data; copy number variation; mutation; bladder cancer recurrence; long non-coding rnas(1)

资金

  1. National Natural Science Foundation of China [81872089, 81672551, 81670632, 81871157, 82070773, 82102831]
  2. Jiangsu Provincial Key Research and Development Program [BE2019751]
  3. Natural Science Foundation of Jiangsu Province [BK20201271]
  4. National Key Research and Development Program of China [SQ2017YFSF090096]

向作者/读者索取更多资源

This study established a ten-lncRNA signature for predicting bladder cancer recurrence based on multi-omics analysis, which showed robust predictive value in training and testing sets and association with immune disorders.
Bladder cancer (BLCA) is one of the most common cancers worldwide with high recurrence rate. Hence, we intended to establish a recurrence-related long non-coding RNA (lncRNA) model of BLCA as a potential biomarker based on multi-omics analysis. Multi-omics data including copy number variation (CNV) data, mutation annotation files, RNA expression profiles and clinical data of The Cancer Genome Atlas (TCGA) BLCA cohort (303 cases) and GSE31684 (93 cases) were downloaded from public database. With multi-omics analysis, twenty lncRNAs were identified as the candidates related with BLCA recurrence, CNVs and mutations in training set. Ten-lncRNA signature were established using least absolute shrinkage and selection operation (LASSO) and Cox regression. Then, various survival analysis was used to assess the power of lncRNA model in predicting BLCA recurrence. The results showed that the recurrence-free survival time of high-risk group was significantly shorter than that of low-risk group in training and testing sets, and the predictive value of ten-lncRNA signature was robust and independent of other clinical variables. Gene Set Enrichment Analysis (GSEA) showed this signature were associated with immune disorders, indicating this signature may be involved in tumor immunology. After compared with the other reported lncRNA signatures, ten-lncRNA signature was validated as a superior prognostic model in predicting the recurrence of BLCA. The effectiveness of the model was also evaluated in bladder cancer samples via qRT-PCR. Thus, the novel ten-lncRNA signature, constructed based on multi-omics data, had robust prognostic power in predicting the recurrence of BLCA and potential clinical implications as biomarkers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据